Alpha Tau Medical Ltd Cl A (DRTS) Stock Price, Quote & News

Company Profile

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical or pending clinical studies for brain and other cancers. The company is headquartered in Jerusalem, Israel.

Industry: Biotechnology

Sector: Healthcare

Phone: 972 3 577 4115

Website: www.alphatau.com

Address:

Kiryat HaMada St. 5, Jerusalem, Israel

Dirtymartini66 Mar. 9 at 9:34 PM

$DRTS - from Ai - search - Alpha Tau DRTS + 4.68% submitted the first FDA PMA module for recurrent skin cancer in January 2026, a key regulatory milestone. - Near-term clinical focus includes ReSTART trial recruitment completion (Q1 2026) and pancreatic cancer pilot data at ASCO in January 2026.

0 · Reply

kareem1988 Mar. 9 at 9:02 PM

$DRTS Alpha Tau Medical FY25 Earnings Net Loss: $42.6M ($0.53/share) vs $31.8M in 2024. Cash Position: Strong $76.9M (up from $62.9M YoY), providing solid runway for 2026 milestones. R&D Spend: Increased to $32.1M as clinical trials ramp up. Wider loss is expected for a clinical-stage biotech, but the Japanese marketing approval for head and neck cancer is a massive de-risking event. With 5 concurrent U.S. trials and $77M in the bank, the focus shifts to the ReSTART pivotal data and pancreatic/GBM readouts later this year.

1 · Reply

mikesterz7 Mar. 9 at 8:41 PM

$DRTS 🚨 Q4 2025 (Full Year 2025): The company reported a net loss of $42.6 million for the full year 2025, a widening from the $31.8 million loss in 2024. Q3 2025: Reported a loss per share (EPS) of -$0.14, missing analyst estimates of -$0.12. Q2 2025: Reported EPS of -$0.13, which was an 18.18% improvement year-over-year from a -$0.11 EPS in Q2 2024. Cash Position: Despite the losses, the company ended 2025 with $76.9 million in cash and cash equivalents, which is expected to fund operations for at least two years

0 · Reply

StockNews_Live Mar. 9 at 8:04 PM

$DRTS 🎯 STOCK NEWS ALERT 💵 Price: $6.71 (+5.23%) 🔥 Sentiment Score: 85/100 🚀 VERY POSITIVE NEWS 📄 Alpha Tau Medical Ltd. reported full year 2025 financial results and provided a corporate update. The company announced receipt of Japanese marketing approval, the fifth parallel U.S. trial approval,… 📎 https://stocknews.live/news/DRTS/alpha-tau-announces-full-24195.html

0 · Reply

StockNews_Live Mar. 9 at 8:04 PM

$DRTS 🎯 STOCK NEWS ALERT 💵 Price: $6.71 (+4.68%) 🔥 Sentiment Score: 85/100 🚀 VERY POSITIVE NEWS 📄 Alpha Tau Medical Ltd. reported full year 2025 financial results and provided a corporate update. The company announced receipt of Japanese marketing approval, the fifth parallel U.S. trial approval,… 📎 https://stocknews.live/news/DRTS/alpha-tau-announces-full-13173.html

0 · Reply

Jessypenny Mar. 9 at 6:05 PM

$DRTS Building new momentum. Lots of buyers taking advantage.

0 · Reply

SlimyMango Mar. 9 at 5:52 PM

$DRTS Another 200 in the Roth for a clean 2500. Nice buying opportunity back under $7

0 · Reply

jackschitt126 Mar. 9 at 5:51 PM

$DRTS Nice turn around

0 · Reply

JohnStocksNY Mar. 9 at 1:42 PM

$DRTS Laat call get your cheap stocks!

1 · Reply

Jordan3333 Mar. 9 at 1:06 PM

$DRTS the talk here for weeks was about Japan, I think the company has bigger things coming, I just don’t know how much they will say in the earnings report this week

3 · Reply

Alpha Tau Announces Full Year 2025 Financial Results and Provides Corporate Update

Feb 24, 2026, 8:51 PM EST - 12 days ago

HekaBio and Alpha Tau Medical Obtain Approval in Japan for Solid Tumor Treatment Alpha DaRT

Feb 24, 2026, 9:00 AM EST - 13 days ago

Alpha Tau Medical Receives Japanese Marketing Approval for Alpha DaRT® in Unresectable Locally Advanced or Locally Recurrent Head and Neck Cancer

Feb 3, 2026, 12:37 PM EST - 4 weeks ago

Altamirano PLLC Issues Investor Notice on Inspired Healthcare Capital (IHC) Chapter 11 Bankruptcy Filing

Jan 29, 2026, 9:00 AM EST - 5 weeks ago

Alpha Tau Issues Letter to Shareholders: Five Concurrent Trials in the U.S. with Multiple Significant Value-Driving Milestones Ahead

Jan 23, 2026, 3:34 AM EST - 6 weeks ago

Alpha Tau Medical: Pancreatic, GBM, And Other Updates; Set Up For A Strong, Catalyst-Rich 2026

Jan 6, 2026, 9:00 AM EST - 2 months ago

Alpha Tau Reports New Positive Results in Two Upcoming Presentations at ASCO GI 2026 Symposium Showcasing Immune-Preservation and High Disease Control in Montreal Pancreatic Cancer Alpha DaRT® Study

Jan 5, 2026, 9:00 AM EST - 2 months ago

Alpha Tau Submits First Pre-Market Approval Module to the FDA for Alpha DaRT® for the Treatment of Recurrent Cutaneous Squamous Cell Carcinoma (cSCC)

Dec 9, 2025, 9:00 AM EST - 3 months ago

Alpha Tau Successfully Treats First Patient in its U.S. Trial for Patients with Recurrent Glioblastoma at the James Cancer Hospital at The Ohio State University

Nov 20, 2025, 4:05 PM EST - 3 months ago

Alpha Tau Announces Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 11, 2025, 8:30 AM EST - 4 months ago

Alpha Tau to Participate at Jefferies Global Healthcare Conference in London

Oct 21, 2025, 8:30 AM EDT - 4 months ago

Alpha Tau Announces Receipt of Radioactive Material License for its New Hampshire Manufacturing Facility, Advancing Towards Commercial Readiness

Oct 17, 2025, 10:04 AM EDT - 5 months ago

Altamirano PLLC Issues Notice to Inspired Healthcare Capital (IHC) Investors on Recovery Options

Oct 16, 2025, 11:55 AM EDT - 5 months ago

Alpha Tau Medical: Localized Alpha Radiation, A New Paradigm In Oncology

Sep 2, 2025, 8:30 AM EDT - 6 months ago

Alpha Tau Successfully Treats First Patient in its U.S. Multi-Center Pancreatic Cancer Clinical Trial

Aug 27, 2025, 8:30 AM EDT - 6 months ago

Alpha Tau to Participate in Five September Investor Conferences

Aug 11, 2025, 4:02 PM EDT - 7 months ago

Alpha Tau Announces Second Quarter 2025 Financial Results and Provides Corporate Update

Jul 25, 2025, 9:04 AM EDT - 8 months ago

Revival Healthcare Capital Announces Strategic Partnership to Accelerate External Innovation in Robotics With up to $458 Million Joint Investment With Olympus Into Co-Founded New Company Swan EndoSurgical

May 19, 2025, 4:01 PM EDT - 10 months ago

Alpha Tau Announces First Quarter 2025 Financial Results and Provides Corporate Update

May 12, 2025, 4:01 PM EDT - 10 months ago

Alpha Tau Announces Appointment of Nadav Kidron to its Board of Directors

May 6, 2025, 8:30 AM EDT - 10 months ago

Alpha Tau to Participate in May Investor Conferences

Apr 28, 2025, 9:00 AM EDT - 11 months ago

Alpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed Pharmaceuticals

ORMP

Apr 28, 2025, 9:00 AM EDT - 11 months ago

Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical

ORMP

Apr 2, 2025, 8:30 AM EDT - 1 year ago

Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Recurrent Glioblastoma

Mar 12, 2025, 4:02 PM EDT - 1 year ago

Alpha Tau Announces Full Year 2024 Financial Results and Provides Corporate Update

Feb 24, 2025, 8:30 AM EST - 1 year ago

Alpha Tau Receives Medical Device Single Audit Program (MDSAP) Certification

Jan 27, 2025, 9:00 AM EST - 1 year ago

Alpha Tau Announces Cornerstone Interim Data Across Multiple Clinical Trials to be Shared at R&D Update Day

Dec 18, 2024, 8:30 AM EST - 1 year ago

Alpha Tau Announces Upcoming Presentation of New Data at 2025 ASCO GI Symposium and at Company R&D Update Day

Dec 17, 2024, 9:00 AM EST - 1 year ago

Alpha Tau Announces Appointment of Maya Netser to its Board of Directors; Board Member Meir Jakobsohn Stepping Down, Staying on as Advisor

Dec 11, 2024, 8:30 AM EST - 1 year ago

Alpha Tau to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 6, 2024, 8:30 AM EST - 1 year ago

Alpha Tau to Participate in Ladenburg's Oncology Innovators & Investors Symposium

Nov 13, 2024, 8:30 AM EST - 1 year ago

Alpha Tau to Participate in Citi's 2024 Global Healthcare Conference and Piper Sandler's 36th Annual Healthcare Conference

Oct 21, 2024, 8:30 AM EDT - 1 year ago

Alpha Tau Announces Acceptance Into FDA's Total Product Life Cycle Advisory Program to Accelerate Market Access to Alpha DaRT® for Patients with Recurrent Glioblastoma Multiforme

Oct 10, 2024, 8:30 AM EDT - 1 year ago

Alpha Tau Treats First Patient with Recurrent Lung Cancer

Sep 20, 2024, 8:30 AM EDT - 1 year ago

Alpha Tau Announces FDA Approval of IDE to Initiate Multi-Center Investigator-Initiated Study of Alpha DaRT® in Immunocompromised Patients with Recurrent cSCC

Aug 22, 2024, 8:30 AM EDT - 1 year ago

Alpha Tau to Participate in the H.C. Wainwright 26th Annual Global Investment Conference, the Sidoti Small-Cap Virtual Investor Conference, the Redburn Atlantic and Rothschild & Co 2024 Radiopharma Conference, and the Lytham Partners Fall 2024 Investor Conference

Aug 14, 2024, 4:02 PM EDT - 1 year ago

Alpha Tau Medical Announces Second Quarter 2024 Financial Results and Provides Corporate Update

Jun 25, 2024, 8:30 AM EDT - 1 year ago

Alpha Tau Announces Publication in Cancers Journal of Long-Term Safety and Efficacy Data in Multiple Hard-to-Treat Superficial Cancers

May 21, 2024, 8:45 AM EDT - 1 year ago

Alpha Tau to Present at the Jefferies Global Healthcare Conference

May 20, 2024, 4:01 PM EDT - 1 year ago

Alpha Tau Medical Announces First Quarter 2024 Financial Results and Provides Corporate Update

May 13, 2024, 8:30 AM EDT - 1 year ago

Alpha Tau Announces Alpha DaRT Treatment of First Patient with Liver Metastases of Colorectal Cancer

May 6, 2024, 8:30 AM EDT - 2 years ago

Alpha Tau Presents Preclinical Data Demonstrating Abscopal Immune Effect in Pancreatic Murine Tumor Models at ESTRO 2024 Congress in Glasgow

Mar 25, 2024, 8:50 AM EDT - 2 years ago

Alpha Tau to Present at the Jefferies Radiopharma Innovation Summit

Mar 7, 2024, 4:01 PM EST - 2 years ago

Alpha Tau Medical Announces Full Year 2023 Financial Results and Provides Corporate Update

Feb 26, 2024, 8:30 AM EST - 2 years ago

Alpha Tau to Participate in Barclays 26th Annual Global Healthcare Conference

Dec 20, 2023, 9:15 AM EST - 2 years ago

Alpha Tau to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Nov 29, 2023, 8:30 AM EST - 2 years ago

Alpha Tau to Participate in Sidoti Small-Cap Conference

Nov 28, 2023, 8:30 AM EST - 2 years ago

Alpha Tau Announces Highly Promising Interim Results from Safety and Feasibility Trial of Alpha DaRT Treatment of Advanced Pancreatic Cancer

Nov 20, 2023, 8:30 AM EST - 2 years ago

Alpha Tau Submits to Japanese PMDA for Pre-Market Approval of Alpha DaRT in Patients with Recurrent Head and Neck Cancer

Nov 16, 2023, 4:30 PM EST - 2 years ago

Alpha Tau Medical Announces Third Quarter 2023 Financial Results and Provides Corporate Update

Dirtymartini66 Mar. 9 at 9:34 PM

0 · Reply

kareem1988 Mar. 9 at 9:02 PM

1 · Reply

mikesterz7 Mar. 9 at 8:41 PM

0 · Reply

StockNews_Live Mar. 9 at 8:04 PM

0 · Reply

StockNews_Live Mar. 9 at 8:04 PM

0 · Reply

Jessypenny Mar. 9 at 6:05 PM

$DRTS Building new momentum. Lots of buyers taking advantage.

0 · Reply

SlimyMango Mar. 9 at 5:52 PM

$DRTS Another 200 in the Roth for a clean 2500. Nice buying opportunity back under $7

0 · Reply

jackschitt126 Mar. 9 at 5:51 PM

$DRTS Nice turn around

0 · Reply

JohnStocksNY Mar. 9 at 1:42 PM

$DRTS Laat call get your cheap stocks!

1 · Reply

Jordan3333 Mar. 9 at 1:06 PM

$DRTS the talk here for weeks was about Japan, I think the company has bigger things coming, I just don’t know how much they will say in the earnings report this week

3 · Reply

urielmd Mar. 9 at 12:55 PM

$DRTS Analysts have a $9.00+ price target and earnings are coming up on Wednesday. This price feels like a steal for the long term.

3 · Reply

JohnStocksNY Mar. 9 at 12:42 PM

$DRTS That’s a great point, with all the news that came out and all the upcoming catalysts it’s crazy to think we’re still under the radar

2 · Reply

Joshsim123 Mar. 9 at 12:41 PM

$DRTS Been watching $DRTS closely since the Japan PMDA approval. The science behind Alpha DaRT is a total game-changer for oncology. With earnings this Wednesday, I’m looking for the 2026 roadmap. The $12 price target feels very realistic.

3 · Reply

JohnStocksNY Mar. 9 at 12:40 PM

$DRTS Cash is ready!

0 · Reply

kareem1988 Mar. 9 at 12:34 PM

$DRTS should be valued at least at 2B$ yet the market cap is at a ridiculous 550M$. what a steal!

1 · Reply

Jordan3333 Mar. 9 at 12:33 PM

$DRTS I’m hoping that all the short term holders are gone and we can resume are up move

2 · Reply

JohnStocksNY Mar. 9 at 11:15 AM

$DRTS Ya’ll ready to reclaim 7?

1 · Reply

kareem1988 Mar. 9 at 10:48 AM

Last week's dip in $DRTS was a gift. Joining $ZEAL , $NVAX , and $VKTX on the "oversold" list today. With $DRTS earnings this Wednesday, the recovery starts NOW. Japan PMDA approval is the floor—the only way is up

1 · Reply

Jessypenny Mar. 9 at 10:29 AM

$DRTS For investors $DRTS might be at the highest upside point in company history. If you are here lets hear how bullish you are on Alpha Tau.

2 · Reply

Ehri Mar. 9 at 6:30 AM

$DRTS strong downtrend because of the war. I'm out

1 · Reply

JohnStocksNY Mar. 9 at 12:55 AM

$DRTS ~12 hours to market open

1 · Reply

Joshsim123 Mar. 8 at 5:12 PM

$DRTS Earnings are coming up for $DRTS this week I’m excited to hear the update and see what’s next for the tech.💪💪

2 · Reply

Market Cap	543.70M
Revenue (ttm)	0.00
Net Income (ttm)	-31.75M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.08

Volume	354,600
Avg Vol	369,172
Day's Range	N/A - N/A
Shares Out	84.82M
Stochastic %K	5%
Beta	1.02
Analysts	Sell
Price Target	$9.67